Pimavanserin (BioDeep_00000182432)

   

human metabolite blood metabolite


代谢物信息卡片


Urea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-n-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1)

化学式: C25H34FN3O2 (427.2634916)
中文名称: 匹莫范色林
谱图信息: 最多检出来源 Homo sapiens(blood) 98.18%

分子结构信息

SMILES: CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C
InChI: InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)

描述信息

D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics
Pimavanserin is a selective inverse agonist of the 5-HT2A receptor with pIC50 and pKd of 8.73 and 9.3, respectively.

同义名列表

10 个代谢物同义名

Urea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-n-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); Bis(1-(4-fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-n-(4-(2-methylpropyloxy)phenylmethyl) carbamide; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-n-(4-(2-methylpropyloxy)phenylmethyl)carbamide; 1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea; Pimavanserin Tartrate; Pimavanserin; Nuplazid; ACP-103; ACP 103



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Kiran Kumar Aalapati, Amit Singh, Ranjana S Patnaik. A Fully Validated UHPLC-MS/MS Method for the Estimation of Pimavanserin in Human (K2EDTA) Plasma and its Application to a Clinical Pharmacokinetic Study. Journal of chromatographic science. 2022 Apr; 60(4):357-363. doi: 10.1093/chromsci/bmab069. [PMID: 34109394]
  • Minhee Kim, Inseon Hwang, Haushabhau S Pagire, Suvarna H Pagire, Wonsuk Choi, Won Gun Choi, Jihyeon Yoon, Won Mi Lee, Jin Sook Song, Eun Kyung Yoo, Seung Mi Lee, Mi-Jin Kim, Myung Ae Bae, Dooseop Kim, Heejong Lee, Eun-Young Lee, Jae-Han Jeon, In-Kyu Lee, Hail Kim, Jin Hee Ahn. Design, Synthesis, and Biological Evaluation of New Peripheral 5HT2A Antagonists for Nonalcoholic Fatty Liver Disease. Journal of medicinal chemistry. 2020 04; 63(8):4171-4182. doi: 10.1021/acs.jmedchem.0c00002. [PMID: 32285676]
  • Essam Ezzeldin, Muzaffar Iqbal, Yousif A Asiri, Azza A Ali, Toqa El-Nahhas. A rapid, simple and highly sensitive UPLC-MS/MS method for quantitation of pimavanserin in plasma and tissues: Application to pharmacokinetics and brain uptake studies in mice. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2020 Apr; 1143(?):122015. doi: 10.1016/j.jchromb.2020.122015. [PMID: 32174544]
  • Clive Ballard, Carol Banister, Zunera Khan, Jeffrey Cummings, George Demos, Bruce Coate, James M Youakim, Randall Owen, Srdjan Stankovic. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. The Lancet. Neurology. 2018 03; 17(3):213-222. doi: 10.1016/s1474-4422(18)30039-5. [PMID: 29452684]
  • Wenying Wu, Yanjie Chu, Shixiao Wang, Xiaoyang Sun, Jingjing Zhang, Yannian Wang, Xiaohui Chen. Investigation of metabolic profile of pimavanserin in rats by ultrahigh-performance liquid chromatography combined with Fourier transform ion cyclotron resonance mass spectrometry. Rapid communications in mass spectrometry : RCM. 2018 Feb; 32(3):269-276. doi: 10.1002/rcm.8025. [PMID: 29105858]
  • Zeyad T Sahli, Frank I Tarazi. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis. Expert opinion on drug discovery. 2018 01; 13(1):103-110. doi: 10.1080/17460441.2018.1394838. [PMID: 29047301]
  • Anna-Lena Nordstrom, Mattias Mansson, Hristina Jovanovic, Per Karlsson, Christer Halldin, Lars Farde, Kimberly E Vanover, Uli Hacksell, Mark R Brann, Robert E Davis, David M Weiner. PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. The international journal of neuropsychopharmacology. 2008 Mar; 11(2):163-71. doi: 10.1017/s1461145707007869. [PMID: 17708779]